Opinion

Video

Patient Selection for Amyloid-Targeting Therapies: Key Characteristics and Considerations

Panelists discuss how ideal candidates for amyloid-targeting therapy typically present with biomarker-confirmed early-stage Alzheimer disease, demonstrate positive amyloid PET scans or CSF biomarkers, exhibit mild cognitive impairment or mild dementia, lack contraindications such as significant cerebrovascular disease or anticoagulant use, have adequate support systems for monitoring and managing potential adverse effects, and would benefit from comprehensive pretreatment evaluations including brain MRI and APOE genotyping.

Video content above is prompted by the following:

  • Could you describe the profile of a patient who would be a candidate for treatment with amyloid-targeting therapy?

Related Videos
4 experts are featured in this series.
5 experts are featured in this series
5 experts are featured in this series
Dr Johnie Rose
AJMC Q&A with Jason Bellet, Dr Geoffrey Rutledge, and Dan Nardi
Andrew Evens, DO
AJMC Q&A with Jason Bellet, Dr Geoffrey Rutledge, and Dan Nardi
4 experts are featured in this series.
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo